- Home
- PYPD vs SST Comparison
PYPD vs SST Comparison
Compare PYPD & SST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PYPD
- SST
- Stock Information
- Founded
- PYPD 2008
- SST 2013
- Country
- PYPD Israel
- SST United States
- Employees
- PYPD N/A
- SST N/A
- Industry
- PYPD Medical/Dental Instruments
- SST Diversified Commercial Services
- Sector
- PYPD Health Care
- SST Consumer Discretionary
- Exchange
- PYPD Nasdaq
- SST Nasdaq
- Market Cap
- PYPD 60.4M
- SST 67.7M
- IPO Year
- PYPD 2020
- SST N/A
- Fundamental
- Price
- PYPD $3.63
- SST $4.57
- Analyst Decision
- PYPD Strong Buy
- SST Strong Buy
- Analyst Count
- PYPD 5
- SST 1
- Target Price
- PYPD $12.00
- SST $10.00
- AVG Volume (30 Days)
- PYPD 87.2K
- SST 25.5K
- Earning Date
- PYPD 11-12-2025
- SST 11-05-2025
- Dividend Yield
- PYPD N/A
- SST N/A
- EPS Growth
- PYPD N/A
- SST N/A
- EPS
- PYPD N/A
- SST N/A
- Revenue
- PYPD N/A
- SST $289,784,000.00
- Revenue This Year
- PYPD N/A
- SST N/A
- Revenue Next Year
- PYPD N/A
- SST $12.20
- P/E Ratio
- PYPD N/A
- SST N/A
- Revenue Growth
- PYPD N/A
- SST N/A
- 52 Week Low
- PYPD $2.30
- SST $2.90
- 52 Week High
- PYPD $3.93
- SST $15.00
- Technical
- Relative Strength Index (RSI)
- PYPD 53.80
- SST 29.65
- Support Level
- PYPD $3.59
- SST $5.21
- Resistance Level
- PYPD $3.88
- SST $6.05
- Average True Range (ATR)
- PYPD 0.15
- SST 0.49
- MACD
- PYPD 0.02
- SST -0.14
- Stochastic Oscillator
- PYPD 67.95
- SST 9.01
About PYPD PolyPid Ltd.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.
About SST System1 Inc.
System1 Inc develops technology and data science to operate a responsive acquisition marketing platform. It serves customers in the areas of health and wellness, automotive, finance, travel, and entertainment. The company's segment includes Owned and Operated Advertising (O&O); and Partner Network. It generates maximum revenue from the Owned and Operated Advertising (O&O) segment. Geographically, it operates in United States and Other countries.